Global Liver Cancer Drugs Market 2026-2030

Description

The global liver cancer drugs market is forecasted to grow by USD 4015.6 mn during 2025-2030, accelerating at a CAGR of 10.2% during the forecast period. The report on the global liver cancer drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by escalating global incidence of hepatocellular carcinoma and primary malignancies, rapid proliferation and approval of novel combination immunotherapies, increasing deployment of precision biomarkers and targeted small molecule inhibitors.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.

Market Scope
Base Year	2025
End Year	2030
Series Year	2026-2030
Growth Momentum	Accelerate
YOY 2026	9.7%
CAGR	10.2%
Incremental Value	$4015.6 mn

Technavio's global liver cancer drugs market is segmented as below:

By Type

Immunotherapy
Targeted therapy

By Drug Class

Targeted therapy drugs
Immunotherapy drugs
Chemotherapeutics
Others

By Route Of Administration

Oral
Injectable
Others

By Distribution Channel

Hospital pharmacies
Retail pharmacies
Online pharmacies
Others

Geography

North America
- US
- Canada
- Mexico
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
Asia
Rest of World (ROW)
Rest of World (ROW)

This study identifies the systematic shift from conventional monotherapies to complex combination protocols as one of the prime reasons driving the global liver cancer drugs market growth during the next few years. Also, growing integration of biomarker-driven diagnostics and precision medicine frameworks and rapid expansion and localization of biosimilars in developing regional economies will lead to sizable demand in the market.

The report on the global liver cancer drugs market covers the following areas:

Global liver cancer drugs market sizing
Global liver cancer drugs market forecast
Global liver cancer drugs market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global liver cancer drugs market vendors that include Accord Healthcare Ltd., Apotex Inc., AstraZeneca Plc, Bayer AG, Bristol Myers Squibb Co., Cipla Inc., Dr. Reddys Laboratories Ltd., Eisai Co. Ltd., Eli Lilly and Co., Exelixis Inc., F. Hoffmann La Roche Ltd., Fresenius Kabi AG, Glenmark Pharmaceuticals Ltd., Innovent Biologics Inc., Ipsen Pharma, Merck and Co. Inc., Sun Pharmaceutical Industries, Teva Pharmaceutical Ltd., Viatris Inc., Zelgen Biopharmaceuticals. Also, the global liver cancer drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Product Code: IRTNTR72448

1 Executive Summary

1.1 Market overview
- Executive Summary - Chart on Market Overview
- Executive Summary - Data Table on Market Overview
- Executive Summary - Chart on Global Market Characteristics
- Executive Summary - Chart on Market by Geography
- Executive Summary - Chart on Market Segmentation by Type
- Executive Summary - Chart on Market Segmentation by Drug Class
- Executive Summary - Chart on Market Segmentation by Route of Administration
- Executive Summary - Chart on Market Segmentation by Distribution Channel
- Executive Summary - Chart on Incremental Growth
- Executive Summary - Data Table on Incremental Growth
- Executive Summary - Chart on Company Market Positioning

2 Technavio Analysis

2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
2.2 Criticality of inputs and Factors of differentiation
2.3 Factors of disruption
2.4 Impact of drivers and challenges

3 Market Landscape

3.1 Market ecosystem
3.2 Market characteristics
3.3 Value chain analysis

4 Market Sizing

4.1 Market definition
4.2 Market segment analysis
- Market segments
4.3 Market size 2025
4.4 Market outlook: Forecast for 2025-2030

5 Historic Market Size

5.1 Global Liver Cancer Drugs Market 2020 - 2024
- Historic Market Size - Data Table on Global Liver Cancer Drugs Market 2020 - 2024 ($ million)
5.2 Type segment analysis 2020 - 2024
- Historic Market Size - Type Segment 2020 - 2024 ($ million)
5.3 Drug Class segment analysis 2020 - 2024
- Historic Market Size - Drug Class Segment 2020 - 2024 ($ million)
5.4 Route of Administration segment analysis 2020 - 2024
- Historic Market Size - Route of Administration Segment 2020 - 2024 ($ million)
5.5 Distribution Channel segment analysis 2020 - 2024
- Historic Market Size - Distribution Channel Segment 2020 - 2024 ($ million)
5.6 Geography segment analysis 2020 - 2024
- Historic Market Size - Geography Segment 2020 - 2024 ($ million)
5.7 Country segment analysis 2020 - 2024
- Historic Market Size - Country Segment 2020 - 2024 ($ million)

6 Qualitative Analysis

6.1 Impact of AI on global liver cancer drugs market
6.2 Impact of geopolitical conflicts on global liver cancer drugs market

7 Five Forces Analysis

7.1 Five forces summary
- Five forces analysis - Comparison between 2025 and 2030
7.2 Bargaining power of buyers
- Bargaining power of buyers - Impact of key factors 2025 and 2030
7.3 Bargaining power of suppliers
- Bargaining power of suppliers - Impact of key factors in 2025 and 2030
7.4 Threat of new entrants
- Threat of new entrants - Impact of key factors in 2025 and 2030
7.5 Threat of substitutes
- Threat of substitutes - Impact of key factors in 2025 and 2030
7.6 Threat of rivalry
- Threat of rivalry - Impact of key factors in 2025 and 2030
7.7 Market condition

8 Market Segmentation by Type

8.1 Market segments
8.2 Comparison by Type
8.3 Immunotherapy - Market size and forecast 2025-2030
8.4 Targeted therapy - Market size and forecast 2025-2030
8.5 Market opportunity by Type
- Market opportunity by Type ($ million)

9 Market Segmentation by Drug Class

9.1 Market segments
9.2 Comparison by Drug Class
9.3 Targeted therapy drugs - Market size and forecast 2025-2030
9.4 Immunotherapy drugs - Market size and forecast 2025-2030
9.5 Chemotherapeutics - Market size and forecast 2025-2030
9.6 Others - Market size and forecast 2025-2030
9.7 Market opportunity by Drug Class
- Market opportunity by Drug Class ($ million)

10 Market Segmentation by Route of Administration

10.1 Market segments
10.2 Comparison by Route of Administration
10.3 Oral - Market size and forecast 2025-2030
10.4 Injectable - Market size and forecast 2025-2030
10.5 Others - Market size and forecast 2025-2030
10.6 Market opportunity by Route of Administration
- Market opportunity by Route of Administration ($ million)

11 Market Segmentation by Distribution Channel

11.1 Market segments
11.2 Comparison by Distribution Channel
11.3 Hospital pharmacies - Market size and forecast 2025-2030
11.4 Retail pharmacies - Market size and forecast 2025-2030
11.5 Online pharmacies - Market size and forecast 2025-2030
11.6 Others - Market size and forecast 2025-2030
11.7 Market opportunity by Distribution Channel
- Market opportunity by Distribution Channel ($ million)

12 Customer Landscape

12.1 Customer landscape overview
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

13 Geographic Landscape

13.1 Geographic segmentation
13.2 Geographic comparison
13.3 North America - Market size and forecast 2025-2030
- 13.3.1 US - Market size and forecast 2025-2030
- 13.3.2 Canada - Market size and forecast 2025-2030
- 13.3.3 Mexico - Market size and forecast 2025-2030
13.4 Europe - Market size and forecast 2025-2030
- 13.4.1 Germany - Market size and forecast 2025-2030
- 13.4.2 UK - Market size and forecast 2025-2030
- 13.4.3 France - Market size and forecast 2025-2030
- 13.4.4 Italy - Market size and forecast 2025-2030
- 13.4.5 Spain - Market size and forecast 2025-2030
- 13.4.6 The Netherlands - Market size and forecast 2025-2030
13.5 Asia - Market size and forecast 2025-2030
- 13.5.1 China - Market size and forecast 2025-2030
- 13.5.2 India - Market size and forecast 2025-2030
- 13.5.3 Japan - Market size and forecast 2025-2030
- 13.5.4 South Korea - Market size and forecast 2025-2030
- 13.5.5 Indonesia - Market size and forecast 2025-2030
- 13.5.6 Thailand - Market size and forecast 2025-2030
13.6 Rest of World (ROW) - Market size and forecast 2025-2030
- 13.6.1 Brazil - Market size and forecast 2025-2030
- 13.6.2 Saudi Arabia - Market size and forecast 2025-2030
- 13.6.3 UAE - Market size and forecast 2025-2030
- 13.6.4 Turkey - Market size and forecast 2025-2030
- 13.6.5 Argentina - Market size and forecast 2025-2030
- 13.6.6 Colombia - Market size and forecast 2025-2030
- 13.6.7 South Africa - Market size and forecast 2025-2030
- 13.6.8 Israel - Market size and forecast 2025-2030
13.7 Market opportunity by geography
- Market opportunity by geography ($ million)
- Data Tables on Market opportunity by geography ($ million)

14 Drivers, Challenges, and Opportunity

14.1 Market drivers
- Escalating global incidence of hepatocellular carcinoma and primary malignancies
- Rapid proliferation and approval of novel combination immunotherapies
- Increasing deployment of precision biomarkers and targeted small molecule inhibitors
14.2 Market challenges
- Severe financial toxicity and regulatory disparities impacting patient access
- Inherent biological heterogeneity and rapid emergence of therapeutic resistance mechanisms
- Complex under-diagnosis patterns and high co-morbidity profiles in cirrhotic populations
14.3 Impact of drivers and challenges
- Impact of drivers and challenges in 2025 and 2030
14.4 Market opportunities
- Systematic shift from conventional monotherapies to complex combination protocols
- Growing integration of biomarker-driven diagnostics and precision medicine frameworks
- Rapid expansion and localization of biosimilars in developing regional economies

15 Competitive Landscape

15.1 Overview
15.2 Competitive Landscape
- Overview on criticality of inputs and factors of differentiation
15.3 Landscape disruption
- Overview on factors of disruption
15.4 Industry risks
- Impact of key risks on business

16 Competitive Analysis

16.1 Companies profiled
- Companies covered
16.2 Company ranking index
- Company ranking index
16.3 Market positioning of companies
- Matrix on companies position and classification
16.4 AstraZeneca Plc
- AstraZeneca Plc - Overview
- AstraZeneca Plc - Business segments
- AstraZeneca Plc - Key news
- AstraZeneca Plc - Key offerings
- AstraZeneca Plc - Segment focus
- SWOT
16.5 Bayer AG
- Bayer AG - Overview
- Bayer AG - Business segments
- Bayer AG - Key offerings
- Bayer AG - Segment focus
- SWOT
16.6 Bristol Myers Squibb Co.
- Bristol Myers Squibb Co. - Overview
- Bristol Myers Squibb Co. - Product / Service
- Bristol Myers Squibb Co. - Key news
- Bristol Myers Squibb Co. - Key offerings
- SWOT
16.7 Cipla Inc.
- Cipla Inc. - Overview
- Cipla Inc. - Business segments
- Cipla Inc. - Key news
- Cipla Inc. - Key offerings
- Cipla Inc. - Segment focus
- SWOT
16.8 Dr. Reddys Laboratories Ltd.
- Dr. Reddys Laboratories Ltd. - Overview
- Dr. Reddys Laboratories Ltd. - Business segments
- Dr. Reddys Laboratories Ltd. - Key news
- Dr. Reddys Laboratories Ltd. - Key offerings
- Dr. Reddys Laboratories Ltd. - Segment focus
- SWOT
16.9 Eisai Co. Ltd.
- Eisai Co. Ltd. - Overview
- Eisai Co. Ltd. - Business segments
- Eisai Co. Ltd. - Key offerings
- Eisai Co. Ltd. - Segment focus
- SWOT
16.10 Eli Lilly and Co.
- Eli Lilly and Co. - Overview
- Eli Lilly and Co. - Product / Service
- Eli Lilly and Co. - Key offerings
- SWOT
16.11 Exelixis Inc.
- Exelixis Inc. - Overview
- Exelixis Inc. - Product / Service
- Exelixis Inc. - Key offerings
- SWOT
16.12 F. Hoffmann La Roche Ltd.
- F. Hoffmann La Roche Ltd. - Overview
- F. Hoffmann La Roche Ltd. - Business segments
- F. Hoffmann La Roche Ltd. - Key news
- F. Hoffmann La Roche Ltd. - Key offerings
- F. Hoffmann La Roche Ltd. - Segment focus
- SWOT
16.13 Ipsen Pharma
- Ipsen Pharma - Overview
- Ipsen Pharma - Business segments
- Ipsen Pharma - Key offerings
- Ipsen Pharma - Segment focus
- SWOT
16.14 Merck and Co. Inc.
- Merck and Co. Inc. - Overview
- Merck and Co. Inc. - Business segments
- Merck and Co. Inc. - Key news
- Merck and Co. Inc. - Key offerings
- Merck and Co. Inc. - Segment focus
- SWOT
16.15 Sun Pharmaceutical Industries
- Sun Pharmaceutical Industries - Overview
- Sun Pharmaceutical Industries - Business segments
- Sun Pharmaceutical Industries - Key news
- Sun Pharmaceutical Industries - Key offerings
- Sun Pharmaceutical Industries - Segment focus
- SWOT
16.16 Teva Pharmaceutical Ltd.
- Teva Pharmaceutical Ltd. - Overview
- Teva Pharmaceutical Ltd. - Business segments
- Teva Pharmaceutical Ltd. - Key news
- Teva Pharmaceutical Ltd. - Key offerings
- Teva Pharmaceutical Ltd. - Segment focus
- SWOT
16.17 Viatris Inc.
- Viatris Inc. - Overview
- Viatris Inc. - Business segments
- Viatris Inc. - Key news
- Viatris Inc. - Key offerings
- Viatris Inc. - Segment focus
- SWOT
16.18 Zelgen Biopharmaceuticals
- Zelgen Biopharmaceuticals - Overview
- Zelgen Biopharmaceuticals - Product / Service
- Zelgen Biopharmaceuticals - Key offerings
- SWOT

17 Appendix

17.1 Scope of the report
- Market definition
- Objectives
- Notes and caveats
17.2 Inclusions and exclusions checklist
- Inclusions checklist
- Exclusions checklist
17.3 Currency conversion rates for US$
- Currency conversion rates for US$
17.4 Research methodology
- Research methodology
17.5 Data procurement
- Information sources
17.6 Data validation
- Data validation
17.7 Validation techniques employed for market sizing
- Validation techniques employed for market sizing
17.8 Data synthesis
- Data synthesis
17.9 360 degree market analysis
- 360 degree market analysis
17.10 List of abbreviations
- List of abbreviations